EVA Pharma Launches First Locally Produced Insulin in Egypt

Egyptian pharmaceutical company EVA Pharma has unveiled its first batch of locally produced insulin glargine, a vital long-acting medication for diabetes patients. The launch results from a 2022 partnership with global pharmaceutical giant Eli Lilly.

Ministry of Health and Population Khaled Abdel-Ghaffar announced that this milestone is a step toward pharmaceutical self-sufficiency, noting that 15.5% of Egyptians are diabetes patients. Local production will reduce reliance on insulin imports, which have reached USD 30 million by September of this year.

This initiative aims to provide high-quality, affordable insulin to over 1 million people with type 1 and type 2 diabetes annually by 2030.